Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Co-administered Niclosamide in Patients Treated With an Established Regimen for Novel Coronavirus Infectious Disease (COVID-19)

NCT04558021 is registered in ClinicalTrials.gov with Imuneks Farma ilac San. Tic. A.S. as lead sponsor.

NCT NCT04558021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04558021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Co-administered Niclosamide in Patients Treated With an Established Regimen for Novel Coronavirus Infectious Disease (COVID-19)
Lead sponsor
Imuneks Farma ilac San. Tic. A.S.
Phase
Phase 3
Overall status
Unknown status
Start date
October 8, 2020
Completion date
February 14, 2021
Enrollment
200 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

covid19